Expression, polymorphism analysis, reticulocyte binding and serological reactivity of twoPlasmodium vivaxMSP-1 protein recombinant fragments

Among the four parasite species causing malaria in humans,Plasmodium vivaxprevails on both the Asian and the American continents. Several antigens from this parasite's erythrocytic stages have been characterised and some of them are considered to be good vaccine candidates. TheP. vivaxmerozoite...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2003-03, Vol.21 (11-12), p.1033
Main Authors: Espinosa, Ana Maria, Sierra, Adriana Yanett, Barrero, Carlos Alberto, Cepeda, Libia Alexandra, Cantor, Elvia Maria, Lombo, Tania Bibiana, Guzmán, Fanny, Avila, Sandra Julieta, Patarroyo, Manuel Alfonso
Format: Article
Language:English
Subjects:
Cloning
Deoxyribonucleic acid
DNA
E coli
Erythrocytes
Genetic diversity
Immunization
Immunogenicity
Laboratory animals
Malaria
Parasites
Parasitic diseases
Peptides
Proteins
Public health
Vaccines
Vector-borne diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among the four parasite species causing malaria in humans,Plasmodium vivaxprevails on both the Asian and the American continents. Several antigens from this parasite's erythrocytic stages have been characterised and some of them are considered to be good vaccine candidates. TheP. vivaxmerozoite surface protein-1 (PvMSP-1) is a 200kDa antigen, thought to mediate the initial contact between the merozoite and the erythrocyte. An effective blockage of this interaction could be important in anti-malarial vaccine design. This study analyses the genetic polymorphism, binding to both reticulocytes and erythrocytes, antigenicity and immunogenicity of two recombinant proteins belonging to the 33kDa PvMSP-1 proteolytic fragment. Both regions showed very low genetic variation, bound reticulocytes with higher affinity than erythrocytes, were recognised by naturallyP. vivax-infected patient sera and were immunogenic when used to immunise rabbits, making them good vaccine candidates againstP. vivax, to be further preclinically tested in theAotusmonkey model.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(02)00660-6